argenx announces closing of global offering
Regulated information March 28, 2022, 10:30 PM CETMarch 28, 2022, 4:30 PM ET Breda, the Netherlands /…
Year: 2022
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19
BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First…
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple…
Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions
NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
DICE Therapeutics Expands Management Team and Board of Directors
Mary Riley, J.D., appointed as general counsel Lisa Bowers, MHSA, and Mittie Doyle, M.D., FACR,…
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy…
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First…
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022…
Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors
-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended…
Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
– Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – REHOVOT,…
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers…
ERYTECH to Participate in the Upcoming April Investor Conferences
ERYTECH to Participate in the Upcoming April Investor Conferences Cambridge, MA (U.S.) and Lyon (France),…
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry…
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety…
Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results
RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), an…
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted…
Soleno Therapeutics Announces Proposed Underwritten Public Offering
REDWOOD CITY, Calif., March 28, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO),…
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company…
Orezone Reports Additional High-Grade Intercepts from P17s Extension and a Significantly Expanded 2022 Exploration Program at the Bomboré Gold Project
Figure 1 P17 Trend Plan Map Figure 2 P17 Trend Long Section Figure 3 Section…